ESTRO Brachytherapy for Prostate Cancer 2018

374 / 884

“Long-term urinary toxicity is low“
“At 5-13 years’ follow-up,
90% of patients have no (RTOG
0) or minimal (RTOG 1) urinairy
morbidity”